KLK3 and prostate carcinoma: For example, the SU.VI.MAX trial found an increased risk of certain cancers in some subpopulations taking an AO combination supplement, specifically an increased risk of melanoma in supplemented women and an increased incidence of prostate cancer in men with an elevated prostate specific antigen at baseline [63].